These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1008 related items for PubMed ID: 22078154

  • 1. Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the tigecycline evaluation and surveillance trial (TEST) between 2004 and 2009.
    Dowzicky MJ.
    Clin Ther; 2011 Dec; 33(12):1964-73. PubMed ID: 22078154
    [Abstract] [Full Text] [Related]

  • 2. Global in vitro activity of tigecycline and linezolid against Gram-positive organisms collected between 2004 and 2009.
    Dowzicky MJ, Chmelařová E.
    Int J Antimicrob Agents; 2011 Jun; 37(6):562-6. PubMed ID: 21497066
    [Abstract] [Full Text] [Related]

  • 3. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007.
    Dowzicky MJ, Park CH.
    Clin Ther; 2008 Nov; 30(11):2040-50. PubMed ID: 19108792
    [Abstract] [Full Text] [Related]

  • 4. Distribution of resistant gram-positive organisms across the census regions of the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial.
    Denys GA, Koch KM, Dowzicky MJ.
    Am J Infect Control; 2007 Oct; 35(8):521-6. PubMed ID: 17936143
    [Abstract] [Full Text] [Related]

  • 5. Activity of tigecycline and comparators against skin and skin structure pathogens: global results of the Tigecycline evaluation and surveillance trial, 2004-2009.
    Namdari H, Tan TY, Dowzicky MJ.
    Int J Infect Dis; 2012 Jan; 16(1):e60-6. PubMed ID: 22104303
    [Abstract] [Full Text] [Related]

  • 6. Antimicrobial susceptibility among Gram-positive and Gram-negative organisms collected from the Latin American region between 2004 and 2015 as part of the Tigecycline Evaluation and Surveillance Trial.
    Vega S, Dowzicky MJ.
    Ann Clin Microbiol Antimicrob; 2017 Jul 12; 16(1):50. PubMed ID: 28701170
    [Abstract] [Full Text] [Related]

  • 7. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).
    Nørskov-Lauritsen N, Marchandin H, Dowzicky MJ.
    Int J Antimicrob Agents; 2009 Aug 12; 34(2):121-30. PubMed ID: 19342205
    [Abstract] [Full Text] [Related]

  • 8. Antimicrobial susceptibility of gram-negative and gram-positive bacteria collected from countries in Eastern Europe: results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) 2004-2010.
    Balode A, Punda-Polić V, Dowzicky MJ.
    Int J Antimicrob Agents; 2013 Jun 12; 41(6):527-35. PubMed ID: 23590898
    [Abstract] [Full Text] [Related]

  • 9. In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011.
    Kanj SS, Whitelaw A, Dowzicky MJ.
    Int J Antimicrob Agents; 2014 Feb 12; 43(2):170-8. PubMed ID: 24315313
    [Abstract] [Full Text] [Related]

  • 10. Antimicrobial susceptibility among gram-positive and gram-negative blood-borne pathogens collected between 2012-2016 as part of the Tigecycline Evaluation and Surveillance Trial.
    Zhang Z, Chen M, Yu Y, Pan S, Liu Y.
    Antimicrob Resist Infect Control; 2018 Feb 12; 7():152. PubMed ID: 30564308
    [Abstract] [Full Text] [Related]

  • 11. LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers).
    Jones RN, Fritsche TR, Sader HS, Ross JE.
    Diagn Microbiol Infect Dis; 2007 Nov 12; 59(3):309-17. PubMed ID: 17720350
    [Abstract] [Full Text] [Related]

  • 12. Antimicrobial susceptibility among gram-negative isolates collected from intensive care units in North America, Europe, the Asia-Pacific Rim, Latin America, the Middle East, and Africa between 2004 and 2009 as part of the Tigecycline Evaluation and Surveillance Trial.
    Bertrand X, Dowzicky MJ.
    Clin Ther; 2012 Jan 12; 34(1):124-37. PubMed ID: 22154196
    [Abstract] [Full Text] [Related]

  • 13. Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST).
    Bouchillon SK, Iredell JR, Barkham T, Lee K, Dowzicky MJ.
    Int J Antimicrob Agents; 2009 Feb 12; 33(2):130-6. PubMed ID: 18995992
    [Abstract] [Full Text] [Related]

  • 14. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan.
    Huang YT, Liao CH, Teng LJ, Hsueh PR.
    Clin Microbiol Infect; 2008 Feb 12; 14(2):124-9. PubMed ID: 18076671
    [Abstract] [Full Text] [Related]

  • 15. Antimicrobial susceptibility among E. faecalis and E. faecium from France, Germany, Italy, Spain and the UK (T.E.S.T. Surveillance Study, 2004-2009).
    Aznar J, Lepe JA, Dowzicky MJ.
    J Chemother; 2012 Apr 12; 24(2):74-80. PubMed ID: 22546761
    [Abstract] [Full Text] [Related]

  • 16. Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008.
    Jones RN, Ross JE, Bell JM, Utsuki U, Fumiaki I, Kobayashi I, Turnidge JD.
    Diagn Microbiol Infect Dis; 2009 Dec 12; 65(4):404-13. PubMed ID: 19913683
    [Abstract] [Full Text] [Related]

  • 17. [In vitro susceptibility to linezolid in methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus strains].
    Efe S, Sinirtaş M, Ozakin C.
    Mikrobiyol Bul; 2009 Oct 12; 43(4):639-43. PubMed ID: 20084917
    [Abstract] [Full Text] [Related]

  • 18. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
    Biedenbach DJ, Bell JM, Sader HS, Fritsche TR, Jones RN, Turnidge JD.
    Int J Antimicrob Agents; 2007 Aug 12; 30(2):143-9. PubMed ID: 17531446
    [Abstract] [Full Text] [Related]

  • 19. The tigecycline evaluation and surveillance trial; assessment of the activity of tigecycline and other selected antibiotics against gram-positive and gram-negative pathogens from France collected between 2004 and 2016.
    Decousser JW, Woerther PL, Soussy CJ, Fines-Guyon M, Dowzicky MJ.
    Antimicrob Resist Infect Control; 2018 Aug 12; 7():68. PubMed ID: 29876099
    [Abstract] [Full Text] [Related]

  • 20. In vitro activity of tigecycline and comparator agents against a global collection of Gram-negative and Gram-positive organisms: tigecycline Evaluation and Surveillance Trial 2004 to 2007.
    Garrison MW, Mutters R, Dowzicky MJ.
    Diagn Microbiol Infect Dis; 2009 Nov 12; 65(3):288-99. PubMed ID: 19733459
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.